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SOMMARIO 
Le cellule staminali della ghiandola mammaria sono un modello per lo studio dei 
processi molecolari che regolano lo sviluppo fisiologico dell’organo e lo sviluppo 
tumorale. Diversamente da molti organi, la ghiandola mammaria incorre in cicli di 
rigenerazione e involuzione associati alla gravidanza. Per questo la ghiandola 
mammaria è uno dei primi organi nel quale si è ipotizzata la residenza di cellule 
staminali. Dal concetto che le cellule staminali regolano la crescita e la 
differenziazione della ghiandola con l’avvento della gravidanza è stato ipotizzato 
che cellule tumorali con proprietà staminali possano contribuire all’eterogeneità del 
tumore. 
Al fine di scoprire come il normale sviluppo dell’architettura della ghiandola 
mammaria sia originata dalle cellule staminali e il ruolo delle cellule staminali 
tumorali nella progressione tumorale, in questo lavoro di tesi è stata indagata la 
funzione di IFITM3. IFITM3 è stato inizialmente identificato dal laboratorio della 
dott.ssa Zucchi nelle cellule LA7, cellule staminali della ghiandola mammaria di 
ratto capaci di differenziare in dome, strutture 2D simili agli alveoli che si formano 
nella ghiandola mammaria durante la gravidanza. È stato dimostrato dal gruppo 
Zucchi che la funzione di IFITM3 dipende dal cambio di localizzazione della 
proteina dal citoplasma alla membrana plasmatica, dove risiede nei lipid raft. 
Questo è stato il punto di partenza di questa tesi di ricerca con lo scopo di 
identificare se IFITM3 partecipi anche alla formazione di strutture tridimensionali 
complesse della ghiandola mammaria (strutture tubulo-alveolari) e se svolga una 
funzione nel mantenimento delle cellule staminali della ghiandola mammaria. Ho 
utilizzato sistemi transienti e stabili per la modulazione dei livelli di espressione di 
IFITM3 in cellule LA7 e in cellule MCF7, una linea cellulare umana di ghiandola 
mammaria. Mentre le cellule LA7 possiedono sia la capacità di generare sfere sia 
di differenziare morfologicamente e funzionalmente in tutti i tipi cellulari e strutture 
3D della ghiandola mammaria, si ritiene che cloni MCF7 utilizzati in questo studio 
non possiedano proprietà di cellule staminali, non formano sfere e possono 
differenziare unicamente in un tipo di struttura 3D, le cisti simili agli alveoli della 
ghiandola mammaria. Abbattendo i livelli di espressione di IFITM3 con siRNA/oligo 
e tecnologia lenti virale ad RNA a forcina corta (shRNA) in cellule impiegate in 
saggi funzionali in condizioni di coltura 3D, ho scoperto che IFITM3 è necessario 
per la formazione di strutture tubulo-alveolari complesse in cellule MCF7 e per il 
mantenimento delle proprietà di auto-rinnovamento delle cellule staminali LA7. 
Dato che le mammosfere e le cisti mammarie rappresentano strutture 3D associate 
rispettivamente a cellule staminali o differenziate, e dato che la sotto-regolazione di 
IFITM3 inibisce la formazione di entrambe, possiamo ipotizzare che IFITM3 abbia 
una funzione diversa in base al tipo cellulare. La sotto-regolazione di IFITM3 in 
cellule staminali LA7 in condizioni di coltura aderenti e non aderenti ha portato ad 
una graduale perdita delle cellule, suggerendo che IFITM3 svolga una funzione 
necessaria al mantenimento dell’auto-rinnovamento delle cellule staminali LA7. In 
cellule MCF7 la sotto-regolazione di IFITM3 ha portato all’incapacità delle cellule di 
formare alveoli senza effetti sulla proliferazione cellulare. La sovra-regolazione di 
IFITM3 sia in cellule LA7 sia MCF7 ha portato alla rapida morte cellulare per un 
meccanismo che è ancora sotto indagine. Complessivamente ho dimostrato che la 
sotto-regolazione di IFITM3 porta alla perdita delle proprietà di auto-rinnovamento 
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e della capacità di essere propagate come cellule staminali delle cellule LA7. La 
sotto-regolazione di IFITM3 in cellule che non hanno proprietà staminali di auto-
rinnovamento porta all’incapacità delle cellule di formare strutture 3D. 
Lo studio dei profili di espressione genica con tecnologia micorarray ottenuti da 
cellule LA7 trattate per la sotto-regolazione di IFITM3 supporta il ruolo di IFITM3 
nella regolazione del ciclo cellulare, nel trasporto vescicolare e nella modificazione 
dello stato cromatinico. Geni coinvolti nella proliferazione cellulare sono stati trovati 
sotto-regolati in seguito alla perdita di IFITM3, insieme a geni del trasporto 
vescicolare (che coinvolgono proteine che mediano la fusione vescicolare, come le 
SNARE) che possono essere collegati a IFITM3 in quanto il ruolo di IFITM3 nel 
prevenire il rilascio delle particelle virali dai compartimenti endosomiali è associato 
alla formazione di un poro di fusione e alla fusione delle membrane. I geni associati 
con la regolazione epigenomica e la proliferazione cellulare suggeriscono che 
IFITM3 possa avere differenti ruoli in cellule staminali e cellule della ghiandola 
mammaria differenziate, dato che questi geni sono coinvolti nel cancro, nella 
crescita cellulare o apoptosi e nel differenziamento cellulare. 
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ABSTRACT 
Mammary stem cells (MaSCs) are a model to understand molecular processes that 
regulate both normal and cancer development. In contrast to many organs, the 
mammary gland undergoes cycles of re-generation and involution associated with 
pregnancy. For this reason, the mammary gland was one of the first organs in 
which stem cells (SCs) were hypothesized to reside. From the concept that SCs 
regulate normal mammary gland growth and differentiation with onset of 
pregnancy, arose the hypothesis that cancer cells with SC properties may 
contribute to tumor heterogeneity. To understand how normal development of the 
mammary gland architecture arises from SCs and the role of CSCs in tumor 
progression, the function of the IFITM3 gene was investigated in this thesis 
research. IFITM3 was initially identified by Zucchi’s lab in LA7 cells, rat mammary 
SCs that differentiate into domes, 2D structures similar to alveoli that form in 
mammary gland at pregnancy. It was demonstrated by the Zucchi group that the 
function of IFITM3 was dependent on its shuttling from the cytoplasm to the plasma 
membrane and being part of lipid rafts. This was the starting point of the thesis 
research with the aims to identify whether IFITM3 also plays a role in the formation 
of more complex three dimensional (3D) mammary structures (tubule-alveolar 
structures) and has a role in MaSCs. I used transient and stable IFITM3 expression 
modulating systems in the LA7 and the human MCF7 mammary cell line. In 
contrast to the rat LA7 SCs that have both the capacity to generate spheres and 
differentiate morphologically and functionally into all the mammary cell types and 
generate tubule-alveolar structures iin 3D culture conditions, the MCF7 clone used 
in this study are not considered to have SC properties, do not form spheres and 
can only form one type of 3D differentiated structure called cysts. Targeting IFITM3 
in these cells, with siRNA/oligos and short hairpin RNA lentiviral technology in 
order to down-regulate the expression of the protein, and by performing functional 
assays in 3D culture conditions, I found that IFITM3 is necessary for the formation 
of complex alveolar structures in MCF7 cells and for self-renewal of LA7 SCs. As 
mammary spheres and mammary cysts represent different 3D structures 
associated with stem and differentiated cells respectively, and since IFITM3 down-
regulation inhibits the formation of both, this suggests that IFITM3 may have 
different functions depending on the cell type. Down-regulation of IFITM3 in LA7 
SCs in both adherent or in non-adherent cultures resulted in a gradual loss in the 
number of cells, suggesting that IFITM3 function is necessary for self-renewal of 
LA7 SCs. In contrast down regulation of IFITM3 in MCF7 cells resulted in the 
inability of the cells to form alveoli with no effect in cell proliferation. IFITM3 up-
regulation in both LA7 and MCF7 cells resulted in rapid cell death by a mechanism 
that is still under investigation. Collectively, I demonstrate, that IFITM3 down-
regulation results in loss of self-renewal and loss of the ability of LA7 to be 
propagated as SCs. While IFITM3 down-regulation in mammary cells that do not 
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have SC self-renewal capacity results in the inability of the cells to generate 3D 
structures. 
Microarray expression experiments, obtained with down-regulation of IFITM3 in 
LA7 cells, support the IFITM3 function in cell cycle regulation, vesicular transport 
and in the modification of the chromatin state. In addition to genes involved in cell 
proliferation found down-regulated with loss of IFITM3, a link among vesicle-
transport genes (involving proteins mediating vesicle fusion, such as SNARE), and 
IFITM3 was also determined, supporting a role of IFITM3 in preventing the release 
of viral particles from endosomal compartments, associated with membrane fusion 
and the formation of a fusion pore. Genes associated with epigenomic regulation 
and cell proliferation suggests that IFITM3 may have multiple and different roles in 
SCs and in differentiated mammary cells since these genes are involved in cancer, 
cell growth or apoptosis and in cell differentiation. 
  
V 
 
INDEX 
 
SOMMARIO ................................................................................................. I 
ABSTRACT ............................................................................................... III 
1 INTRODUCTION ................................................................................. 1 
1.1 Mammary gland development ....................................................... 1 
1.1.1 Embryonic development ........................................................ 2 
1.1.2 Pubertal stage ....................................................................... 4 
1.1.3 Lactation and involution ......................................................... 6 
1.1.4 Mammary gland stem cells .................................................... 8 
1.2 Breast cancer ................................................................................ 9 
1.2.1 Cancer stem cell theory ....................................................... 10 
1.3 LA7 cell model ............................................................................. 12 
1.4 IFITM3 ......................................................................................... 14 
1.4.1 IFITM3 as cellular defense against viruses .......................... 14 
1.4.2 IFITM3 post translational modifications ................................ 18 
1.4.3 IFITM3 structure and topology ............................................. 20 
1.4.4 IFITM3 in development ........................................................ 21 
1.5 Epigenetic and cancer ................................................................. 22 
2 AIM .................................................................................................... 25 
3 MATERIALS AND METHODS........................................................... 26 
3.1 Cell culture conditions ................................................................. 26 
3.2 Cysts formation assay ................................................................. 26 
3.3 Sphere formation assay .............................................................. 26 
3.4 3D structure formation assay in collagen culture ......................... 26 
3.5 Gene knock down with antisense oligonucleotide ........................ 27 
3.6 shRNA and lentiviral technology .................................................. 27 
3.7 Designing and generation of rat and human IFITM3-eGFP fusion 
protein suitable for rat and human protein localization. ................ 28 
VI 
 
3.8 Fluorescence activated cell sorting .............................................. 28 
3.9 RNA extraction and quantitative pcr ............................................ 29 
3.10 Microarray expression and bioinformatic data analysis ................ 31 
4 RESULTS .......................................................................................... 33 
4.1 Tubule formation assay ............................................................... 33 
4.2 Cysts formation assay ................................................................. 35 
4.3 Sphere formation assay .............................................................. 37 
4.4 eGFP fusion protein .................................................................... 41 
4.5 Role of IFITM3 in LA7 cells proliferation ...................................... 46 
4.6 Microarray analysis ..................................................................... 48 
4.7 RT-PCR validation....................................................................... 53 
5 DISCUSSION .................................................................................... 56 
5.1 Role of IFITM3 in mammary gland differentiation ........................ 56 
5.2 Role of IFITM3 in cancer stem cells and mammary gland stem 
cells ............................................................................................. 57 
5.3 Role of IFITM3 in proliferation ..................................................... 58 
5.4 Role of IFITM3 in vesicular transport ........................................... 59 
5.5 Role of IFITM3 in epigenetic regulation ....................................... 60 
6 CONCLUSIONS ................................................................................ 62 
7 BIBLIOGRAPHY ............................................................................... 63 
 
  
1 
 
1 INTRODUCTION 
1.1 MAMMARY GLAND DEVELOPMENT 
The mammary gland is a branched tubular organ unique to mammals and 
provides nourishment, hormones, antibodies and growth factors to new 
born offspring. The mammary gland architecture is composed of lobes 
containing secretory lobules and alveoli, hollow cavities that produce milk, 
and ducts that converge into a single lactiferous duct for each lobe (Fig.1). 
Ducts are bilayered tubuli with an inner layer of luminal epithelial cells and 
a basal layer of myoepithelial cells with contractile capacity due to 
expression of smooth muscle actin. The duct system is embedded in a 
dense connective tissue composed of fibroblast and adipose tissue called 
the fat pad.  
 
 
Figure 1. A) Schematic representation of mammary gland anatomy, multiple ducts are in different 
color, all converging into the nipple. The lobule are embedded into the fat pad. B) Histological 
section of a lobule of mammary gland, stained with hematoxylin and eosin (nuclei appear in blue). 
In the corner magnification of an acinus, the functional milk producing structure of the gland. 
Modified from 
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. 
The mammary gland has the peculiar feature of undergoing structural and 
cellular remodeling in multiple stages of development during the lifespan of 
the female individual (Fig.2).  
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Figure 2. Schematic representation of mammary gland development. The embryo develops the 
placode and the primitive nipple. With puberty the ducts elongate and the branching 
morphogenesis take place. In pregnancy the gland reaches it maximum expansion with the 
formation of alveoli and after weaning the involution phase brings the gland to a state similar to a 
pre-pregnancy state
2
. 
 
1.1.1 EMBRYONIC DEVELOPMENT  
The first step takes place during embryonic development with the formation 
of the mammary lines that are bilateral stripes that extend from the anterior 
to posterior limbs.  
The origin of the mammary line is tightly influenced by the surrounding 
mesenchyme and continuous crosstalk between the epithelia and fibroblast 
compartments3. The specification of the mammary line depends on the 
expression of the WNT genes in the ectoderm and flanking mesenchyme4,5, 
under the regulation of FGF106 signaling from ventral somites. FGF10 
along with WNT and BMP4 regulate the expression of the Tbx3 gene in the 
mesenchyme underlying the mammary line6–8, which as a result amplifies 
WNT signalling leading to the formation of placodes.  
Five pairs of placodes in mouse and one in human9 are formed by 
aggregation of epidermal cells of the mammary line10 which become 
columnar and multilayered. In the next days the placodes invaginate into 
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the mesenchyme forming structures that are shaped like buds that infiltrate 
into the underlying primitive fat pad. This process is dependent on WNT4 
and the transcription factors MSX1 and MSX211,12. 
The epidermal bud sprouts through the stroma until it reaches the pre-
adipocytes cells and it starts to branch into a rudimental ductal tree in a 
hormonal independent fashion13,14. Branching is followed by cavitation of 
the primordial ducts, and by nipple formation and sexual dimorphism in 
mice. In male the ducts are severed by growth of the surrounding 
mesenchyme under androgen hormone influence (Fig.3). 
 
 
Figure 3. Mammary gland development of mouse. At day 10.5 the mammary line is formed, in 
following days the epithelial cells will change shape and organize into the placode. Placode 
invagination forms the epidermal bud, infiltrating thorough the adipocytes of the fat pad. The 
sprout reaches the fat pad and the primordial ductal tree is formed, with the development of the 
nipple. Modified from
15
.  
PTHLH is responsible for this final stage of embryonic development, acting 
through its mesenchymal receptor PTHR1 modulating BMP4 and WNT 
signaling16,17 that will induce the formation of an environment that will 
support the survival of the epithelial bud, nipple development and growth of 
the duct system. At this stage the development stops and will proceed in 
the adult life during puberty.  
At the pre-pubertal stage the mammary gland is composed of simple ducts 
poorly infiltrated into the fat pad, ending in terminal end buds (TEBs) which 
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are club shaped structures with a multiple layer of epithelial cells (body 
cells) surrounded by more basal cells forming the cap cell layer18,19.  
1.1.2 PUBERTAL STAGE  
At puberty TEBs are stimulated to infiltrate into the fat pat and start the 
branching morphogenesis process that will remodel the architecture of the 
gland. Secondary branches grow from the primary elongated ducts and in 
the further weeks, tertiary branches will follow. 
The branching morphogenesis is under the control of growth factors and 
hormones such as IGF, EGF, FGF, HGF, GH, estrogen and TGF, that act 
directly or indirectly on the epithelial cells, stimulating the fibroblast and 
surrounding mesenchyme compartments in a paracrine fashion. The 
pituitary gland releases Growth Hormone, which reaches the stroma of the 
mammary gland through the blood stream and binds to the Growth 
Hormone Receptor20. Fibroblasts are stimulated to produce IGF1, which 
acts along with hepatic IGF1 on epithelial cells through the IGF1R, 
stimulating proliferation and cell survival21 (Fig.4). 
Estrogens have a direct effect on mammary branching22, as many gene 
knockout mouse models have shown 23–25. Estrogens receptors are 
expressed in fibroblasts of the stroma and epithelial cells, after ligand 
binding to the fibroblasts produce and release more IGF1 while the 
epithelial cells produce amphiregulin (AREG). AREG is a member of the 
EGF family and is cleaved by ADAM17, a metalloproteinase expressed by 
luminal cells26. Once free, AREG binds to EGFR on stromal cells and acts 
in a paracrine way to stimulate the production and release of FGF. FGF will 
then bind to FGFR on epithelial cells and promote cell proliferation and 
branching.  
EGFR activates also other matrix metalloproteinases that positively 
regulate the branching process27, degrading the extracellular matrix 
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creating space for the elongation of the TEBs, with cap cells differentiating 
into myoepithelial cells during elongation28. 
 
 
Figure 4. Schematic representation of the growth factors regulating duct elongation. MMPs are 
involved in the collagen degradation
29
. 
 
TEB elongation is dependent of the expression of tissue inhibitors of 
metalloproteinases (TIMPs), which spatially regulate the activity of MMPs 
within the stromal/luminal surface and by TGF. TGF acts by inhibiting 
both duct elongation and branching, limiting the movement of the TEBs and 
allowing for a properly organized tree architecture30, and promoting ECM 
deposition31, creating distant spaced branched buds. ECM involvement in 
branching morphogenesis is not only due to its physical spatial effect, but 
also involves sequestration of growth factors released by proteinase that 
may also produce bioactive fragments of ECM itself. 
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1.1.3 LACTATION AND INVOLUTION 
The final stage of mammary gland development takes place during 
pregnancy and following involution after weaning, a cyclic process that 
occurs at each pregnancy. Lactation is the ultimate function of the 
mammary gland. During pregnancy the mammary gland will increase its 
internal complexity completely filling the fat pad, and differentiate creating 
the specialized structures dedicated to milk production and delivery.  
Progesterone (PR) and prolactine (PRL) are the hormones leading the 
modification of the mammary gland in this last stage. PR is responsible for 
the massive extension of the branches, and with PRL triggers the 
differentiation of luminal cells into alveoli32–34. PRLR involves the 
JAK2/STAT5 signalling cascade, that not only promotes the production of 
milk proteins and enzymes but is also responsible for the differentiation and 
maintenance of the alveolar cell state35–37. PR and PRL both exert their 
actions through modulating RANKL signalling in a paracrine fashion. 
RANKL binds to its receptor on epithelial cells starting a cascade that will 
induce proliferation and block apoptosis38–40.  
The final involution takes place at offspring weaning, when mechanical 
stimulation of milk production by suckling ceases. Remodelling of the 
mammary gland then initiates that will bring the gland back to a pre-
pregnancy state. Two steps distinguish this last phase (Fig.5), the first one 
involves accumulation of milk and apoptotic process with accumulation of 
dead cells in the ducts, without massive remodelling of the tree 
architecture. This first step can be reversed by re-initiation of suckling 
stimulation within 48 hours. 
The second, takes place in the next days and is irreversible, with a new 
apoptotic process linked to the ECM degradation41. A switch between 
STAT5 and STAT3 occurs in the first hours of weaning, with consequent 
suspension of pro-survival input and start of the apoptotic process42,43, 
triggered by the Leukemia Inhibitory Factor (LIF) produced by the alveolar 
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cells in response to suckling withdrawal44. Many target of STAT3 are up-
regulated in response to LIF, such as C/EBPdelta45 or the regulatory 
subunits of the PI3K46 that reduce the anti apoptotic activity of AKT.  
The extrinsic death program is also involved, with ligands binding to the 
death receptors, activation of the FAS/FASL pathway and promotion of 
apoptosis47,48, with IGF1 sequestration by IGFBP5, reducing its pro survival 
effect49. 
 
Figure 5. Involution takes place when the milk request to stop. The first reversible phase occurs 
within the first 48 hours after cessation of suckling. Milk accumulation lead to release of LIF and 
apoptosis. The second phase is irreversible and involves remodelling of the extracellular matrix. 
Modified from 
50
. 
 
The final and conclusive step of involution involve proteinases for a 
complete degradation of ECM, with the activation of hepatic plasminogen to 
plasmin, which can directly degrade the ECM51, and MMPs such as MMP2, 
3 and 9 which are no more inhibited by TIMPs 51,52. Protease influences the 
multiplication and differentiation of new adipocytes releasing growth factors 
from the ECM 53,54 for a process that promote cell expansion with recreation 
of a fat pad similar to the pre-pregnancy state.  
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1.1.4 MAMMARY GLAND STEM CELLS 
As the mammary gland undergoes rounds of remodelling throughout the 
female lifespan, and cycles of cellular expansion and tissue remodelling are 
dependent on cells with multi-lineage differentiation and self-renewal 
potential, these suggest the existence in the mammary gland of cells with 
stem cell (SC) properties. Stem cell survival relies on a stem cell niche, a 
microenvironment that provides the signals necessary for the maintenance 
of self renewal and the undifferentiated state of stem cells.  
First observations of the regenerative potential of the mammary gland 
came from graft experiments of Deome and Faulkin55. Transplantation of 
mouse epithelial cells into mammary fat pad cleared of host’s epithelia 
showed that these cells were able to create a branched tree in the fat pad, 
and that the transplantation could be repeated with grafted epithelial cells 
into a cleared fat pad of another mouse. 
Cell dilution analysis of mammary epithelial cells showed to contain three 
different lineage restricted progenitors, which can differentiate into ducts, 
alveoli or a complete mammary gland56, raising the question if mammary 
gland development is due to cooperation of lineage committed progenitors 
or if a single multipotent stem cell that could be responsible of the complete 
formation of the gland.  
Kordon and Smith used the mouse mammary tumor virus (MMTV) to 
investigate the clonal origin of the mammary gland. They transplanted 
infected epithelial cells into a healthy non-MMTV mouse and discovered 
that primary and secondary outgrowth had the same genomic insertion 
sites of MMTV. These studies supported that the mammary epithelium 
originates clonally by a single mammary epithelial cell57.  
Moreover, epithelial cells can be serially transplanted without losing their 
properties, and are not influenced by the age of the donor, confirming the 
stem cells feature of epithelial cells58,59.  
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In the following years many groups attempted to isolate a cell population 
with the stem cell features, using marker labelling or dye retention 
associated with Fluorescence Activated Cell Sorting (FACS). In the late 
2000s mouse mammary stem cells were successfully isolated using CD24, 
CD29 and CD49f as markers60,61(Fig.6). 
 
 
Figure 6. Differentiation hierarchy of mammary gland. In blue and red the surface markers used 
for isolation of mouse and human cells, respectively. A MaSC originates a common progenitor for 
luminal and myoepithelial line, which will differentiate to committed progenitors
62
. 
 
A similar approach with different markers lead to identification of MaSCs in 
human 63,64. 
 
 
1.2 BREAST CANCER 
Breast cancer is the second most common cancer worldwide for women. 
Breast cancer is a very heterogeneous disease which can be classified by 
molecular profiles that allows for more specific therapy and prediction of 
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clinical outcome. Human breast cancer can be grouped by the expression 
of the estrogen receptor, progesterone receptor and human epidermal 
growth factor receptor 2 (HER2), or by their absence (triple negative 
cancer), and into subtypes such as luminal A, luminal B, basal like, HER2 
like, and claudin low and normal 65–68.  
Luminal A tumors are characterized by expression of the ER and/or PR, but 
are negative for HER2; luminal B, like A, express ER and/or PR and are 
also positive for HER2. The HER2 like tumors are positive for HER2 and 
negative for PR and ER, while the basal like are triple negative breast 
cancer marked by the expression of basal cytokeratins such as CK5/6, 
CK14, and CK17. Claudin low are triple negative breast cancers which 
express low levels of the claudin gene and factors involved in the EMT 
process69. 
Breast cancer progression is divided into different stages depending on the 
location and size of the tumor, the invasion of lymph nodes and presence of 
metastasis. The original carcinoma in situ can grow in size and invades 
adjacent tissue of the skin or the chest wall of the breast. Cancer stages of 
development are formulated by combination of previous criteria, with the 
final stage that involves metastasis of the cancerous cells that have spread 
to other parts of the body of the patient.  
1.2.1 CANCER STEM CELL THEORY 
Breast cancer originates from a transforming event in a single cell, by 
accumulation of mutations resulting in the expansion and clonal selection of 
a tumor single cell. Breast cancer is characterized by heterogeneity both 
among tumors in different individuals and among population of cells within 
the same tumor. Inter-tumor heterogeneity origin is difficult to study, as it is 
nearly impossible to individuate the first transforming cell, as rarely 
diagnosis take place when the tumor is in its earliest stages of development 
allowing to follow its molecular evolution. Intra-tumor heterogeneity is due 
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to the presence of cancer cells with different phenotypes, or epigenetic 
chromatin states.  
To explain tumor heterogeneity two models have been proposed, the clonal 
evolution and the cancer stem cell model (Fig.7). 
 
 
Figure 7. A) Cancer stem cell model, the cancer stem cell is the only one that maintains self 
renewal properties. Daughter cells form the mass of the tumor but don’t contribute to 
accumulation of new mutations. B) The clonal evolution model. Each cell can acquire the self 
renewing properties and contribute to tumor progression
70
. 
 
In the clonal evolution each cell can be a tumor initiating cell, which starts 
from initial mutations that provides unlimited proliferation. Individual cancer 
cells may gain new mutations that can confer advantages against other 
clones, spreading heterogeneity.  
In the cancer stem cell model the tumor starts from mutations in a subset of 
cells with normal stem cell like properties, or progenitor cells that regain self 
renewal potential. A cancer stem cells behave as a normal SCs, with 
asymmetric cell division potential that maintain the stem pool with daughter 
stem cells and cells which differentiate into all cell types of the body, 
explaining the heterogeneity.  
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First observations of cancer stem cells came from the hematopoietic field71, 
where the cell capable of initiating an acute myeloid leukemia in mouse 
possessed proliferative, differentiative and self renewal potential as 
expected from a stem cell. In 2003 breast cancer stem cells were 
identified72, confirming the validity of the cancer stem cell model in breast 
tumors.  
 
 
1.3 LA7 CELL MODEL 
LA7 cells were first isolated from the RAMA-25 cell line derived from an 
adenocarcinoma chemically induced in rat by Dulbecco in 198073. 
The group of Zucchi demonstrated that LA7 cells are a model of cancer 
stem cells and can be used to study both normal mammary gland and 
breast cancer development. LA7 cells have the stem cell properties74,75 of: 
self-renewal that can be maintained indefinitely in vitro and in vivo, multi 
lineage differentiation as they have the ability to generate branched ductal-
alveolar-like structures in three-dimensional (3D) cultures that 
morphologically and functionally recapitulate the tubule-alveolar 
architecture of the mammary tree. In addition, exposure of LA7 cells to 
lactogenic hormones, lipids, or differentiating agents (e.g. DMSO) results in 
the formation of dome-shaped structures filled with liquid, that recapitulate 
the cellular changes that occur in the mammary gland at pregnancy, when 
alveoli are formed (Fig.8). 
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Figure 8. A) LA7 cells cultured in adherent conditions grow forming colonies originated from a 
single epithelial cell known as holoclone. B) When cultured in non adherent conditions LA7 
generate spheres from a single cell with stem cell properties. C) LA7 grown in confluent 
conditions, spontaneously or treated with differentiating agents, differentiate into D) Domes. E) 
Tubular structures formed by LA7 cells when cultured in 3D conditions. Red arrows point at TEBs. 
Modified from
74,76
. 
 
LA7 cells have tumor initiation capacity, as one single LA7 is sufficient to 
develop a tumor in NOD-SCID mouse, and single cells isolated from the 
dissociated tumor tissues are similar to the injected LA7 in terms of 
differentiative potential, self renewal and tumor initiation capacity. LA7 also 
have metastatic potential. LA7 are therefore an ideal model to study breast 
cancer and breast development in all its facets phases. 
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Figure 9. A) LA7 cultured in adherent conditions to differentiate into domes. B) A magnification of 
A, showing staining of IFITM3 in domes cellular membrane
77
 
Zucchi’s lab demonstrated that LA7 differentiation into domes is dependent 
on a gene, rat8, identified during the study of domes differentiation78 
(Fig.9). Rat8 is the rat homologous to human IFITM3 and my thesis 
research will investigate the role of IFITM3 in other aspects of mammary 
gland development. 
 
 
1.4 IFITM3 
1.4.1 IFITM3 AS CELLULAR DEFENSE AGAINST VIRUSES 
Interferon stimulated Transmembrane protein 3 (IFITM3) is a member of 
the interferon stimulated genes (ISGs), and basally expressed in many 
tissues and up-regulated in response to Interferon I and II stimulation79,80.  
IFITM3 is member of the family of the IFITMs, these proteins are highly 
conserved among species and mostly similar among each other; in human 
there are five members of the family: IFITM1, IFITM2, IFITM3, IFITM5 and 
IFITM10 (Fig.10). IFITM5 is specifically expressed in bone cells and is not 
interferon responsive81. Most mammals and other vertebrates have 
orthologs of these proteins. In mouse there are also the forms IFITM6 and 
IFITM7.  
A B 
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IFITM1 was first identified in a study in which targeting the protein by an 
antibody resulted in T lymphocyte aggregation, the antigen was named 
Leu-1382 a domain common to all IFITMs, the CD225. IFITIM1 was also the 
first member of the family to be related to viral resistance. Cells in which 
IFITM1 is up-regulated are partially protected from the vesicular stomatitis 
virus (VSV)83.  
IFITM3 was first identified by the Zucchi’s lab78 in subtractive library of 
differentiating versus undifferentiated LA7. 
Identification of viral protection activity of IFITM3 (Brass publication on Cell) 
was first seen from: Influenza A Virus (IAV), HIV, Dengue virus and West 
Nile virus84, demonstrating the efficiency of IFITM proteins in blocking the 
infection of enveloped viruses. IFITM3 mainly co-localizes with ER markers 
and was also shown be able to move to the plasma membrane.  
 
Figure 10. Cluster of IFITM family members in human, mouse and rat. Arrows indicate the 
direction of transcription. Modified from
85
. 
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Further experiments by other laboratories demonstrated a protective role of 
IFITMs against other viruses: SARS corona virus, Marburg (MARV) and 
Ebola (EBOV) filovirus, but MARV and EBOV cell entry was less restricted 
by IFITM3 with respect to the IAV86. Moreover Huang and colleagues 
hypothesized that IFITM3 mediated restriction could be related to the 
alteration of the endosomal or lysosomal compartments, as IFITMs do not 
influence the cathepsin L activity necessary for viral fusion.  
Interestingly IFITM3 seems to have a role also in interfering with viral 
translation87. In a STAT1 stable expressing cell line IFITM3 up-regulation 
reduced the translation efficiency of viral proteins, as confirmed by 
luciferase assays. This result suggested a putative regulatory role of 
IFITM3 by its interaction with RNA or DNA by its leucine zipper domain, as 
suggested by another paper in which IFITM3 expression reduce the level of 
the osteopontin (OPN) mRNA 88. 
These main investigations on IFITM3 are related to the discovery of the 
mechanisms of action as antiviral protection. The Brass laboratory89 found 
that IFITM3 inhibited nuclear translocation of viral pseudo particles and 
their hemoagglutinin (HA) or VSV’s envelope glycoprotein (VSV-G) 
mediated fusions. Endosomes are membrane bounded compartment 
implicated in the vescicular transport of the endocytic pathway from plasma 
membrane to lysosome. IFITM3 is shown to be localized in the late 
endosomes and exogenous overexpression of the protein or INF treatment 
resulted in volume expansion and increase of endosome number.  
IFITM3 localization into endosomes results in viruses being trapped inside 
the vesicle compartment, failing to fuse with the membrane and unable to 
proceed with the following cytosolic entry. The endosomes fuse with 
lysosomes and viral particles are then degraded.  
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Another study from Li and colleagues suggest that IFITMs plays a role in 
preventing viral hemifusion by altering the curvature of endosomal 
membrane90. Hemifusion is promoted by negative curvature and IFITMs 
may instead confer a positive curvature. Moreover IFITMs may alter the 
fluidity of the lipidic membrane, reducing the ability of the lipids to undergo 
movements necessary for achieving hemifusion.  
Alteration in cholesterol homeostasis has been linked to IFITM3 antiviral 
activity, with IFITM3 interaction with Vesicle-membrane-protein-associated 
protein A (VAPA) and oxysterol-binding protein (OSBP) causing an 
accumulation of cholesterol in the endosomes, thus stiffening the 
endosomal membrane and inhibiting viral fusion91.  
Brass and collaborators found that amphotericin B, an antimycotic 
commonly used in clinical treatment, was responsible for a decreased 
restriction of viral infection by IFITM3 in treated tissue cultures92. This 
finding is consistent with the proposed way of action of IFITM3 involving 
membrane stiffness, as amphotericin B is known to bind to lipids and to 
increase membrane fluidity. They investigated also the role of cholesterol 
and VAPA on IFITM3 mediated restriction, and found that neither 
cholesterol nor VAPA does not altered the protective effect of IFITM3. 
Desai and collaborators agree with these findings, as they directly enriched 
the cholesterol content of endosomes and evaluated virus-endosome 
fusion capability, which resulted unaltered compared to untreated cells93.  
Their findings suggest that IFITM3 is not involved in regulating the 
hemifusion process, but instead contributes to stabilize the cytoplasmatic 
leaflet preventing the formation of a complete fusion pore. The putative 
mechanism of action of IFITM3 suggested by their results imply a direct 
action on the site of arrested hemifusion, as a barrier to stop viral entry, or 
indirectly modifying the cytoplasmic leaflet protein and or lipid, or 
disallowing viral back-fusion (a proposed two-step mechanism of fusion 
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with the viral particle that first fuse with a vesicle inside the maturing 
endosome, and later with the endosomal membrane).  
1.4.2 IFITM3 POST TRANSLATIONAL MODIFICATIONS 
IFITM3 can be subjected to many post translational modifications such as 
phosphorylation, ubiquitination, palmitoylation and methylation. The post 
translational modifications influence IFITM3 cellular localization, stability 
and anti-viral activity.  
S-palmitoylation at cysteines 72, 73 and 1094 enhances affinity of IFITM3 to 
the cell membrane, increasing its antiviral activity, without altering its 
localization . Ubiquitination at lysines 24, 83, 88 and 104 instead diminishes 
the IFITM3 mediated viral restriction, since mutations at ubiquitin binding 
residues increase antiviral activity95.  
The other fundamental modification is phosphorylation at tyrosine 20 by 
FYN kinase96. Phosphorylation regulates IFITM3 localization and thus its 
antiviral activity since phosphorylated proteins are localized at the plasma 
membrane level and IFITM3 is required at endosomal level to protect the 
cell from viral invasion. The majority of IFITM3 proteins are un-
phosphorylated and at endosomal level. 
Tyrosine 20 is part of the YEML aminoacidic sequence recognized by the 
μ2 subunit of the AP-2 complex, which is responsible for IFITM3 
internalization (Fig.11). Phosphorylation alters the capacity of the complex 
to bind and promote clathrin mediated endocytosis97.  
It is also known that IFITM3 can influence clathrin dependent endocytosis 
of v-ATPase98 suggesting that IFITM3 may play a role organizing proteins 
at plasma membrane for subsequent internalization. 
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Figure 11. Schematic representation of IFITM3 trafficking and shuttling to plasma membrane. In 
the corner IFITM3 is shown ubiquitinated at cysteine 24 and palmitoylated. The complex AP-2 
bind IFITM3 at the YEML motif with the subunit μ2 and undergoes clathrin dependent 
endocytosis
97
. 
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1.4.3 IFITM3 STRUCTURE AND TOPOLOGY 
IFITM proteins share common domains that are divided into a hydrophobic 
N-terminal domain, a conserved hydrophobic intramembrane domain, a 
conserved intracellular loop, a hydrophobic transmembrane domain and a 
short C-terminal domain. The CD225, shared by all members of the family, 
includes the intramembrane domain and intracellular loop.  
IFITM3 topology is a very discussed argument, as many models have been 
proposed in the last years. The first one assumes a topology similar to 
IFITM1, a type III transmembrane protein, with C and N terminals facing the 
extracellular space, as the N-terminal domain is targeted by the antibody 
causing aggregation of cells, and both can be detected by flow cytometry 
and immune-staining, suggesting exposure to the extracelluar side of the 
membrane82,90.  
Nevertheless, other data suggest a different topology for IFITM3. The 
protein can be subject to post-translational modifications such as 
ubiquitylation95 and phosphorylation96, those modifications require an N-
terminal cytoplasm oriented and accessible to ubiquitin ligase and kinase.  
Palmitoylation on conserved and non-conserved residues of murine IFITM1 
supported the cytosolic orientation of the C terminus99, allowing the 
formulation of a model with both N and C terminus being intracellular. A 
recent study on murine IFITM3 proposes a new topology, with the N-
terminal and conserved internal loop intracellular and the C-terminal 
extracellular100 (Fig.12). The authors also observed in some cellular models 
an alternate topology with the N-Term extracellular, but it is not known if it 
is a complete inversion of the protein or is involving only the N-terminus. 
The frequency of the alternate topology is unknown but its existence 
emphasizes the fact that IFITM3 may change topology under unknown 
circumstances that are cellular dependent, according also to old literature 
results.  
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Figure 12. IFITM3 represented as a type II transmembrane protein. N-term and the loop between 
the two idrophobic domain are intracellular, whereas the C-term region is extracellular or facing 
the inside of endoplasmic reticulum or endosomal lumen. Modified from 
100
. 
1.4.4 IFITM3 IN DEVELOPMENT 
IFITM3 plays a role also in embryonic homing of primordial germ cells 
(PGCs), where it is expressed and promotes homotypic adhesion of PGC 
precursors to form a cell cluster in the posterior epiblast101. In cooperation 
with IFITM1, which is expressed by PGC precursors and later in the 
endoderm and repels the PGCs, IFITM3 is necessary for homing of the 
cells, as cells ectopically expressing IFITM3 tend to localize to the PGC 
domain in the posterior endoderm102. 
Surani’s group created a mouse model in which IFITM3 or all IFITMs family 
were deleted, surprisingly no appreciable effect was noticed. Mice were 
fertile and no defects on development or adult life were observed. Deletion 
of the entire cluster of the IFITMs highlighted that no redundancy could 
occur, and single deletion of IFITM3 did not disrupt any putative interaction 
between family members. 
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The investigators propose that discrepancy with previous results may be 
due to different technical approaches used by Surani and Tanaka’s 
laboratories. Tanaka used siRNA technology to silence IFITM1 and 3, 
whereas Surani used targeted mutation to obtain the loss of function, 
suggesting that previous results could depend on side effect of siRNA 
used. Moreover, Tanaka used an experimental model that may suffer delay 
in development due to the strain or passage of the ESCs used to generate 
embryos, and since PGCs migration is an event that occurs early in 
development any slight delay could be significant.  
Surani suggest that previous results should be reconsidered in view of their 
finding. 
IFITM3 is a fundamental gene for mammary gland development. IFITM3 
was first identified in a screening among cells that can differentiate into 
domes under treatment with differentiating agents and cells that are unable 
to form those structures78. Down-regulation of IFITM3 by targeted oligos 
inhibited dome formation capacity of LA7 cells, and oligo treatment on 
already formed domes lead to collapse of the structures. 
IFITM3 in undifferentiated cells is localized to Golgi whereas in domes it 
stays at the plasma membrane. FYN77 is required for differentiation of LA7 
in domes, as it associates with IFITM3 that shuttle to lipid raft domains of 
the plasma membrane, and as we do know now96,103 Fyn phosphorylates 
IFITM3 and regulates its localization. 
 
 
1.5 EPIGENETIC AND CANCER 
Epigenetics is defined as changes in gene expression due to modifications 
of DNA or histones in a non permanent way. Epigenetics is a dynamic 
process that influences cell behavior and can be influenced by changes in 
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the physiology of the organism. Epigenetic modifications include DNA 
methylation, histone methylation, acetylation and phosphorylation. 
DNA methylation is a post replication modification step that occurs at 
cytosines in CpG islands, regions rich in cytosines and guanines positioned 
at the 5’ of genes104, and is catalyzed by DNA methyl transferase (DNMT).  
Histone modifications occur at the N-terminal domains of proteins and are 
catalyzed by the enzymes: histone acetyltransferases (HATs), histone 
deacetylases (HDACs), histone methyltransferases (HMTs), and histone 
demethylases (HDMs). The combined modifications involving histones 
create a complex of information and instructions named “histons code”, that 
can influence affinity of DNA binding proteins and thus their activity105,106. 
Acetylation of histones H3 and H4 are associated with active transcription 
whereas hypo-acetylated histones are associated with inactive genes. 
Phosphorylation of histone H3 is correlated to chromosome condensation 
during mitosis107,108 and is necessary for a coordinate segregation of 
chromosomes without loss of genetic information109. 
HMTs catalyze methylation of histones H3 and H4 at lysines or arginines110 
K9111, K4112, 27 and 36. The lysine residues can accept one, two or three 
methyl groups. Histone methylation can be associated with active 
transcription or gene silencing depending on the number of methyl groups 
bound 113,114. 
As previously mentioned, breast cancer is a heterogeneous disease which 
insurgence is related to mutations in oncogene or tumor suppressor genes. 
Epigenetic alteration of the physiological state of the cells are related to 
cancer, since tumor suppressor DNA repair genes can be silenced by 
promoter methylation, resulting also in an increase of genome instability 
and mutations115. In breast cancer there is evidence of hypermethylation of 
tumor suppressor genes or hypomethylation of oncogenes such as BRCA1, 
p16 or TMS1116,117. For instance, detection of CpG islands methylation of 
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the promoter of APC, CDH1, and CTNNB1 showed their involvement in 
cancer onset and progression118. 
In ER negative cancers, histone modifications and DNA methylation is 
involved in ER regulation. For instance, HDAC1 and DNMT1 are 
responsible for the transcriptional repression of the receptor and their 
inhibition by drug treatment can restore ER expression119,120.  
Another example of epigenetic involvement in breast cancer is EZH2, the 
enzymatic component of the polycomb repressive complex 2 responsible 
for lysine 17 methylation on histone 3.EZH2 up-regulation correlates with 
aggressive cancer and poor prognosis. EZH2 dysregulation promotes 
invasion in vitro and in vivo and could be used as a biomarker for 
aggressive tumor detection121. 
The epigenetic state of tumor cells and level of enzymes involved in 
epigenetic modifications can thus be fundamental for early diagnosis and 
prediction of the evolution of the tumor and also for therapeutic treatment. 
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2 AIM 
Our previous research demonstrated that IFITM3 is necessary for 
polarization and homotypic adhesion of epithelial cells in the formation of 
domes. 
The aim of this thesis research is to investigate the role of IFITM3 in lumen 
formation of complex 3D structures associated with mammary gland 
development and specifically to investigate the role of IFITM3 in the 
maintenance of the stem cell properties and in the the luminal cell function 
using rat mammary CSCs and human mammary cancer cells as model 
systems. 
We hypothesize that since IFITM3 has a role in 3D lumen structure 
formation, loss of or down-regulation IFITM3 protein it may contribute to or 
tumor formation by promoting loss of cell polarity, loss of cell adhesion and 
consequently allowing cell invasion. 
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3 MATERIALS AND METHODS 
3.1 CELL CULTURE CONDITIONS  
LA7 cells were cultured in DMEM (Invitrogen), 10% fetal bovine serum 
(FBS, Gibco Laboratories), supplemented with 50 ng/mL insulin and 50 
ng/mL hydrocortisone. Cells were harvested with 0,05% trypsin (Invitrogen) 
containing 0,53 mM EDTA (Gibco Laboratories). 
MCF7 cells were cultured in RPMI (Invitrogen), 10% fetal bovine serum, 
supplemented with 10 µg/mL insulin. Cells were harvested with 0,05% 
trypsin containing 0,53 mM EDTA. 
3.2 CYS FORMATION ASSAY 
For cysts formation MCF7 were seeded 500 cells/mL in culture medium 
and fresh medium was added every two days. 
3.3 SPHERE FORMATION ASSAY 
For sphere formation LA7 were seeded, at clonogenic density, in culture 
medium containing 0.5X B27 without vitamin-A (Gibco Laboratories), 10 
ng/mL EGF, 10 ng/mL bFGF (Sigma) and 4 μg/mL heparin (Sigma) in low 
attachment plates (Bibby Sterilin). 
3.4 3D STRUCTURE FORMATION ASSAY IN COLLAGEN 
CULTURES 
Monolayer cultures were detached by trypsinization, mixed with collagen 
derived from rat tails in ratio 1:2 and plated at a concentration of 2500 
cells/well in 24 multi-well plates. After collagen had solidified, 500 μL of 
medium, was added. Medium was refreshed by replacing and half of 
medium every 2-3 days. 
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3.5 GENE KNOCK DOWN WITH ANTISENSE 
OLIGONUCLEOTIDES 
The antisense oligomer (AS-IFITM3) sequence was designed as a 
complementary sequence to the 5’end of the IFITM3 coding region, and the 
sense oligomer (S-IFITM3) from the same coding sequence but in opposite 
orientation: AS-IFITIM3 5’-TTTCGTAGTTTGGGGGTTGT-3’ and S-IFITM3 
5’-ACAACCCCCAAACTACGAAA-3’. The oligos were used at dosage of 40 
μg/mL. The cells were pre-treated after plate attachment for 72 hours and 
then used to generate spheres and tubuli. Fresh oligos were then added to 
the cells at every change of medium during tubuli and sphere formation. 
3.6 shRNA AND LENTIVIRAL TECHNOLOGY 
To stably down-regulate IFITM3 expression we prepared a construct 
containing a short hairpin RNA construct to target IFITM3 transcript (5’-
TGCTGTGACAGAAGCCGATCCGTGGGGTTTTGGCCACTGACTGACCC
CACGGAGGCTTCTGTCA-3’) and cloned it into the pDrive cloning vector. 
The shRNA was then moved to pCDH-CMV-MCS-EF1-copGFP construct 
by digesting the pDrive cloning vector with the endonuclease BamHI and 
NotI (New England Biotechnologies). 
A lentiviral approach was used to allow for the genomic integration and 
constitutive expression of the shRNA to down-regulate IFITM3 expression. 
Lentiviral components were produced in HEK293 cells by transfecting the 
pCDH vector together with psPAX2 and pMD2.G using the Lipofectamine 
2000 transfection reagent (Life Technologies) according to manufacturer’s 
instruction. The medium of culture containing the viral particles was 
harvested after 48h and 72h from the time of transfection and precipitated 
with the PEG-it Virus Precipitation Solution (System Bioscience) according 
to manufacturer’s instruction. 
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Cells were transduced adding lentiviral preparation to culture medium 
additionated with 8μg/ml Polybrene (Sigma). 
3.7 DESIGNING AND GENERATION OF RAT AND HUMAN 
IFITM3-eGFP FUSION PROTEIN SUITABLE FOR RAT AND 
HUMAN PROTEIN LOCALIZATION. 
To follow real time the localization of IFITM3, a fusion protein with the 
enhanced Green Fluorescent Protein (eGFP) was produced. The coding 
sequence of the protein without the stop codon was inserted upstream the 
eGFP. 
The rat IFITM3-eGFP fusion vector was generated cloning by PCR the 
CDS of rat IFITM3 without the stop codon from the pDRIVE with the 
following primer pairs FOR 5’-CGGAATTCATGAACCACACTTCT-3’ and 
REV 5’-TCGTCTCCAGACTGGATCCCG-3’. The PCR product was 
digested with restriction enzymes EcoRI and BamHI and inserted into the 
linearized peGFP-N3 (Clontech, discontinued). 
The human IFITM3-eGFP fusion vector was generated cloning by PCR the 
CDS of human IFITM3 from the pCDH with the primer pairs FOR 5’-
CGCGGGCCCGGGATCAGTGTGCTGGAATTCG-3’ and REV 5’-
TGGTGGCGATGGATCCTCCATAGGCCTGGAA-3’. The PCR product was 
inserted in the peGFP-N3 digested with BamHI using the In-Fusion™ 
Advantage PCR Cloning Kit (Clontech) and the peGFP-N3 linearized with 
BamHI. 
3.8 FLUORESCENCE ACTIVATED CELL SORTING 
Fluorescence Activated Cell Sorting (FACS) was performed with a FACS 
Canto II cytometer (BD Biosciences) and the software FACS Diva (BD 
Biosciences). Cells were harvested with 0,05% trypsin (Invitrogen) 
containing 0,53 mM EDTA (Gibco Laboratories) and washed with PBS prior 
to perform the analysis. 
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3.9 RNA EXTRACTION AND QUANTITATIVE PCR 
Total RNA was extracted using the TRIzol® (Life Technologies) reagent 
following manufacturer’s instruction. RNA was reverse transcribed using 
High Capacity RNA Master Mix and mRNA expression was evaluated by 
Real Time PCR with SYBR Green (Applied Biosystems) with a 7500 Real 
Time PCR System (Applied Biosystems). 
RT-PCR was performed on LA7 cells transfected/transduced with either 
siRNA oligos or with the lentivirus containing shRNA for the down-
regulation of IFITM3. Untreated cells were used as control. 
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Species Gene Gene Bank ID Forward primer Reverse primer 
Rat Ifitm3 NM_001136124.1 CACGGATCGGCTTCTGTCA AGCCCAGGCAGCAGAAGTT 
Rat Hprt1 NM_013556 TCCATTCCTATGACTGTAGATTTTATCAG AACTTTTATGTCCCCCGTTGACT 
Rat Olr1378 NM_214828.1 CCCATGCTGAACCCTTTTATTT CCAGTTTTTGTAGAGCCCCTTTC 
Rat Olr1471 NM_001000722.1 CCCTGTTCCTGTCCATGTACCT GAAGGACAAGTTGCTGAGAAAAAAG 
Rat Olr866 NM_001000411.1 ATGATTCCAGGCAAGAACCAA GGTCACTGGAGAAGCCAATCAG 
Rat Suv39h1 NM_001106956.1 CGAGGAGCTCACCTTTGATTACA AGGCCAAAGTTGGAGTCCATT 
Rat Setdb1 NM_001271175.1 TGGCTCTGATGGCGATGA TTTTACTGCCACCTGACGCTTT 
Rat Prmt3 NM_053557.1 AGTGGATGGGCTATTTTCTTCTTTTT CAAGTATTTGCTCTTGGCATAAAGG 
Rat Kdm1b NM_001107343.1 TGGTCCAGCAGGCTTAGCA GACAGTCACCTTCATCCCAAAGT 
 
Table 1. Primers for RT-PCR. Hprt1 is used as house keeping gene. 
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3.10 MICROARRAY EXPRESSION AND BIOINFORMATIC DATA 
ANALYSIS 
Total RNA of LA7 cells siRNA transfected or lentivirus transduced for the 
down-regulation of IFITM3 and untreated cells was extracted using TRIzol® 
(Life Technologies) following manufacturer’s instruction. Expression profile 
analysis performed using the GeneChip® Rat Gene 1.0 ST Array according 
to manufacturer’s instruction (Affymetrix). 
The microarray expression analysis was performed to obtain the "Robust 
Multichip Average" (RMA)122 which takes into account subtraction of the 
background signal, quantile normalization and sum of the value of the 
probes belonging to the same set. The quality of the normalized data was 
evaluated generating different charts explorers, such as the density 
distribution of the signal, principal component analysis, logarithmic 
expression and the relative dependence of the variance from the mean. 
The differential expression of each gene among groups of different samples 
was calculated using the Student t-test moderate123. The p-value 
associated with the t statistics moderate was used to calculate the values of 
FDR (false discovery rate) associated with the genes. Analysis were 
performed using the R language124 and software packages written in R that 
contains implementations of the methods described above. 
The top 500 genes with the highest absolute fold changes were considered 
as differentially expressed. In all comparisons such genes had an absolute 
log2 fold change greater than log2 (1,5). 
Pathway analysis was carried out using the hypergeomtric and using NCBI 
Biosystems database as source of rat gene-pathway associations. 
Pathways with FDR adjusted p-value < 0.05 were considered as significant. 
A second analysis was performed on gene, in order to cluster genes with 
the same Gene Ontology, or belonging to the same pathway or by known 
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interaction using the bioinformatics tools DAVID126,127, Panther128 and 
KEGG 129,130. 
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4 RESULTS 
4.1 TUBULE FORMATION ASSAY 
It was previously demonstrated that LA7 cells have stem cell properties and 
are therefore represent an in vitro and ex situ model for studying the 
differentiation programs of the mammary gland and the properties of self 
renewal. 
LA7 cells when cultured in 3D culture conditions, form tubular structures 
similar to mammary gland ducts. Additionally, LA7 cells generate in 
adherent culture conditions, blister like 2D structures called domes that 
morphologically and functionally recapitulate alveoli that form in mammary 
gland at late pregnancy. We hypothesized that the role of IFITM3 in the 
formation of 2D-like structures was also required for the formation of 3D 
structures such as tubuli and acini. Therefore to investigate the role of 
IFITM3 in the formation of more complex 3D structures, tubule formation 
and cyst assays were developed in our lab using rat tail collagen.  
Different approaches were undertaken to evaluate the effect of the 
inhibition of IFITM3 in the 3D structure formation capacity of cells. In one 
assay LA7 cells were cultured in adherent conditions and pre-treated with 
antisense oligo targeting Ifitm3 in order to down-regulate the level of mRNA 
and protein, then cells were then embedded in collagen (Fig.13). In other 
assays LA7 cells were seeded in collagen in the presence of the oligos and 
treated after collagen solidification (Fig.14). In agreement with IFITM3 
being essential for 2D structure formation, as shown for dome formation, 
experimental results show that inhibition of IFITM3 protein synthesis 
resulted in no capacity of LA7 cells to generate complex three dimensional 
structures such as tubuli (Fig.13, 14). 
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Figure 13. Collagen culture assay with antisense IFITM3 (AS)-oligos pre-treatment. LA7 cells were 
pre-treated for 72 hours prior to embedding them into 3D collagen, and subsequently also treated 
during collagen cultures. After 10 days of culture control cells show branched tubuli (A), while cells 
treated with AS-IFITM3 do not form tubuli (B). 4X Magnification. 
Figure 14. Collagen culture assay with no As-oligo pre-treatment. Tubuli formation. Cells were 
embedded in collagen in the presence of the oligos and treatment occurred after collagen 
solidification. Control cells show branched tubuli (A) after 7 (left, 4X magnification) and 10 days 
(right, 20X magnification). Cells treated with As-IFITM3 do not develop tubuli (B) after 7 days (left) 
or at 10 days (right) of culture. 
A 
 
 
 
B 
A 
 
 
 
 
 
B 
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4.2 CYSTS FORMATION ASSAY 
As repression of IFITM3 is associated with impairment of dome formation in 
LA7 cells, and IFITM3 protein is also expressed in human mammary cells, I 
tested whether the inhibition of IFITM3 would also inhibit 3D structure 
formation of human mammary epithelial cells. We therefore used MCF7 
cells, an epithelial cell line originated from a human adenocarcinoma, which 
are known for their ability to form cysts, alveolar like structures reminiscent 
of the mammary gland alveoli. To overcome the difficulty of the continuous 
treatment/transfection of the oligos we generated lentiviral constructs to 
stably down-regulate IFITM3 expression. For the constitutive inhibition of 
IFITM3 expression a construct containing a short hairpin RNA to target 
IFITM3 human transcript was generated to allow for the genomic 
integration and constitutive expression of the shRNA to down-regulate 
IFITM3 expression. shRNA expression is under the control of 
cytomegalovirus (CMV) promoter, whereas the GFP is under the control of 
Human elongation factor-1 (EF-1). We choose to use a GFP expressing 
vector in order to have a reporter which can be used to individuate cells 
positively transduced, and quantitatively estimate the efficiency of 
transduction. 
After 15 days of culture MCF7 cells untreated or transduced with the empty 
GFP lentivirus formed spherical structures hollow inside (Fig.15 A to D). 
Conversely MCF7 cells transduced with the shRNA for IFITM3 lentivirus 
are unable to form cysts and the cells can only form aggregates in which a 
lumen is absent (Fig.15 E and F). In the experiments in which cells were 
transduced with the shRNA for IFITM3 lentivirus, uninfected cells 
uninfected and thus not expressing the construct for the down-regulation of 
IFITM3, were still able to form cysts (Fig.15E arrows). 
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Since IFITM3 is necessary for the formation of cysts-like structure also in 
human mammary cells, results support the role of IFITM3 in mammary 
gland development. 
 
 
Figure 15. Cyst structure formation by MCF7 cells cultured in non adherent conditions. A and B) 
Un-transduced or GFP transduced MCF7 cells (C and D) form spherical structures hollow inside 
called cysts after 15 days of culture. E and F) MCF7 transduced with the shRNA targeting human 
IFITM3 lentivirus. Cells positive to GFP are expressing the shRNA and fail to develop into cysts and 
form aggregates. Red arrows point a cyst negative to GFP, in which there is no down-regulation of 
IFITM3. 4X magnification. 
A       B 
 
 
 
 
 
C       D 
 
 
 
 
 
E       F 
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4.3 SPHERE FORMATION ASSAY 
Our group and others have demonstrated that the capacity of cells to 
generate spheres in non-adherent conditions is a property that defines 
mammary SCs and CSCs131. To investigate the role of IFITM3 in MaCSs 
we tested the capability of LA7 cells either treated with IFITM3 antisense 
oligos (Fig.16) or transduced with a lentiviral construct constitutively 
expressing a shRNA targeting IFITM3 (Fig.17) and evaluated for their 
capacity to form spheres in non-adherent cultures conditions. 
 
Figure 16. Spheres formation assay. Control cells (A, 4X magnification) show capability of sphere 
formation, while cells treated with As-IFITM3 form aggregates but no spheres (B, 20X 
magnification). 
Control cells cultured without oligo treatment and cells treated with sense 
oligos (designed from the same coding sequence of IFITM3, not able to 
pair to IFITM3 mRNA and promote its degradation) generated spheres, 
while IFITM3 antisense oligo treated LA7 were unable to form spheres 
(Fig.16). The same experiment was repeated with LA7 cells transduced 
with lentivirus containing the shRNA targeting IFITM3 or the empty GFP 
vector and similar results were obtained. LA7 transduced with a lentivirus 
expressing shRNA targeting IFITM3 form aggregates but not spheres 
(Fig.17, A and B) while control LA7 transduced with the empty GFP vector 
formed spheres after 6 days of culture (Fig.17, C). As single La7 CSCs 
have the capacity to regenerate spheres indefinitely, lack of sphere 
A                                        B  
38 
 
formation with transient or stable down-regulation of IFITM3 would help in 
providing insight into whether the expression of IFITM3 is required for self-
renewal of LA7 CSCs. Taken together these results suggest an 
involvement of IFITM3 in the maintenance of stem cell properties of LA7 
cells. 
 
 
 
Figure 17. A,B) LA7 cells transduced with lentivirus expressing a shRNA targeting rat IFITM3. After 
6 days of non adherent culture there are no spheres observable. LA7 cells in which IFITM3 is 
down-regulated can form only aggregates. In the upper panel the GFP filter is showing the 
population positive to down-regulation of IFITM3, in the above panel the phase contrast. 4X 
magnification.. C) LA7 cells transduced with the empty GFP lentivirus. Control cells positive to GFP 
are able to grow in non adherent conditions and to form spheres. 10X magnification. 
A 
 
 
 
B 
 
 
 
C 
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Spheres generated by the LA7 cells in contrast to cysts generated by 
MCF7 cells (Fig.15) do not contain lumen. These results suggest that 
IFITM3 may have a different function in sphere formation to respect to the 
previously identified role in lumen formation78 in domes or cysts (Figure 15). 
As previously demonstrated by Zucchi’s lab LA7 spheres are generated by 
single cell and LA7 spheres can be regenerate indefinitely, the observed 
lack of sphere formation with down-regulation of IFITM3 suggest that the 
expression of IFITM3 is required for self-renewal of LA7 CSCs.  
Data also suggest that continuous IFITM3 expression is required for 
maintaining CSCs as supported by the observation that transient down-
regulation of IFITM3 with siRNA oligos result in the permanent loss in the 
ability of LA7 CSCs to regenerate spheres. In addition, in long term cultures 
in which IFITM3 was down-regulated in LA7 cells a significant loss of GFP 
positive cells was observed. While this result needs to be further 
investigated, an intriguing conclusion is that expression of IFITM3 may not 
just be required for CSC self-renewal but for cell survival. Closer 
investigations, suggested that the decrease in cell number observed with 
IFITM3 down-regulation, was concomitant with trypsin-dependent 
passaging step, where the cells are removed as adherent cultures from the 
plates and are made into single cell suspensions. With each disruption of 
the cells into single cells, it was observed that in the condition in which 
IFITM3 was down-regulated fewer cells had the ability to re-attach 
suggesting that re-expression of IFITM3 is essential to allow the cells to 
attach to the tissue plate surface. These results may also suggest that re-
expression of IFITM3 after trypsinization is essential to inhibit anoikis 
following the disruption of cell-cell contact. Determining whether cell 
trypsinization combined with the down-regulation of IFITM3 resulting in 
decrease cell numbers is caused by induction of a cell death pathway (e.g., 
anoikis) or by the inability of the cells to re-attach to the tissue culture plate, 
needs to be further investigated.  
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In parallel experiments in rat myoepithelial like cells that express low levels 
of native IFITM3 compared to the LA7CSs (Fig.18) the down-regulation of 
IFITM3 resulted in no loss in cell propagation capacity (Fig.19). This control 
experiment supports that loss of self-renewal observed with down-
regulation of IFITM3 in LA7SCs is specifically due to down-regulation of 
IFITM3 expression and shows the specificity of the effect of shRNA for 
IFITM3. 
 
Figure 18. Real Time data of IFITM3 expression in LA7 cells in comparison to myoepithelial cells. A 
strong difference of IFITM3 expression approximately of 95% is evident. Vertical bars represent 
the standard error of the 95% level of confidence. 
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Figure 19. Rat myoepitheial cells that express low levels of IFIMT3 compared to LA7 CSCs can be 
propagated indefinitely with down-regulation of IFITM3. Myoepithelial like cells generated from 
LA7 CSC transduced with the shRNA for rat IFITM3 after 11 days of culture. The myoepitheial cells 
express low levels of IFIMT3 compared to LA7 CSCs. A) Fluorescent and merged fluorescent and 
bright field (B) images of cells showing cell positive for GFP. 40X magnification. 
The intriguing conclusion is that expression of IFITM3 may not just be 
required for CSCs self-renewal but for cell survival. Whether IFITM3 
expression is essential and how the expression functions in regulating self-
renewal SC or CSC self-renewal is under investigation with on-going 
research by the lab of Zucchi. 
4.4 eGFP FUSION PROTEIN 
Since it is reported that the cellular function of IFITM3 is dependent on its 
ability to migrate from endosomal compartment to plasma membrane77 we 
decided that following the shuttling of the protein during differentiation of 
the cells was of high interest for understanding IFITM3 involvement in the 
process.  
To achieve this goal constructs expressing a chimeric protein of rat and 
human IFITM3 fused with the eGFP were designed and generated. 
LA7 transfected with the rat IFITM3-eGFP fusion construct showed 
cytosolic staining of IFITM3 24 hours after transfection (Fig.20). Since 
down-regulation of IFITM3 suggested that LA7 CSCs displayed decreased 
cell survival, it was surprising to see that up-regulation of IFITM3 also 
42 
 
resulted in significant cell death, as indicated by the fact that cells 
expressing the IFITM3-eGFP fusion protein decreased over time compared 
to the GFP control expressing cells.  
eGFP positive staining was detected in IFITM3-eGFP floating cells with 
fluorescent microscopic imaging (Fig.21). In contrast to the cell loss 
observed with down-regulation of IFITM3, which appeared to be a relavitely 
slow process dependent on trypsinizaiton and passaging of the of cells in 
adherent culture, cell death with the fusion protein in which IFITM3 was up-
regulated occurred rapidly after the GFP protein was expressed. The 
increase cell death with up-regulation of IFIMT3 compared to cell loss with 
IFITM3 down-regulation may suggest that there are differet functions of 
IFITM3 depending on its expression level. For instance, we hypothesize, 
down-regulation-dependent loss of the cell number in in vitro cultures is due 
to a loss of a cell surface and cell-to-cell contact, while up-regulation of 
IFITM3 induced cell death by an unknown mechanism that is at the 
moment under investigation. 
 
Cell death induced with over expression of IFITM3 was not consideredd to 
be due to a non-specific or off-target effect because even cells with the 
lowest expression of the fusion protein (as measured by eGFP expression) 
died relatively quickly after the fusion protein was detected by fluorescence.  
Many of the dead and floating cells showed a positive staining for IFITM3-
eGFP (Fig.21). 
In the next days positive vital cells transfected with IFITM3-eGFP were no 
more detectable, whereas cells transfected with the empty control vector 
resulted alive up to 72 hours after transfection (Fig.22). 
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Figure 20. A) LA7 cells 24 hours from transfection with rat IFITM3-eGFP fusion protein. B) LA7 in 
phase contrast merged with GFP staining. 40X magnification. 
 
Figure 21. LA7 cells 24 hours from transfection with rat IFITM3-eGFP fusion protein. A) The 
majority of positive cells, highlighted in red, resulted dead. B) LA7 in phase contrast merged with 
GFP staining. 40X magnification. 
 
Figure 22. LA7 cells 72 hours from transfection with empty eGFP fusion protein. A) Staining of 
eGFP can be observed in LA7 cells. B) LA7 in phase contrast merged with GFP staining. 10X 
magnification. 
A     B 
A     B 
A     B 
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Figure 23. A) MCF7 cells 24 hours from transfection with human IFITM3-eGFP fusion protein. B) 
Phase contrast picture of MCF7 cells. 40X magnification. 
 
Figure 24. MCF7 cells 24 hours from transfection with human IFITM3-eGFP fusion protein. A) The 
majority of positive cells result dead, highlighted in red. B) LA7 in phase contrast merged with GFP 
staining. 40X magnification. 
  
Figure 25. GFP fusion protein expression in MCF7 at 7 days after transfection. Fluorescent (A) and 
merged fluorescent and bright field (B) images, 40X magnification. In contrast to cells expressing 
the IFITM3-eGFP fusion protein the cells do not display aberrant cell morphology and do not 
detach from the tissue culture plate. 
A     B 
A       B 
A     B 
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MCF7 were also transfected with human IFITM3-eGFP fusion protein. As 
for the rat IFITM3-eGFP fusion protein, perinuclear staining was observed 
(Fig.23). Also in MCF7 cells, expression of IFITM3-eGFP fusion protein is 
accompanied with aberrant cell morphology and cell detachment from the 
culture plates at the onset of fusion protein expression (Fig.24). In fact 
shortly after transfection, cells expressing IFITM3-eGFP have mostly 
detached from the plate surface, while control cells expressing only the 
GFP protein can survive even after one week (Fig.25). 
 
 
Figure 26. A)LA7 cells expressing a protein fused with eGFP localized into nuclei after 24 hours of 
transfection. No cell death was observed after transfection. B) LA7 in phase contrast merged with 
GFP staining. 40X magnification. 
 
To assess whether the IFITM3-GFP fusion protein induces cell death due 
to non-specific activity or off-target effects, LA7 CSCs were transfected with 
a fusion protein generated from GFP and IRF1 protein used as a control 
transcription factor protein (Fig.26). The IRF1-eGFP fusion protein localized 
into nuclei as expected for a transcription factor and no cell death was 
observed in long term cultures (shown for 72 hours from transfection). 
The expression analysis suggests that cell viability is impaired with human 
and rat IFITM3-eGFP expression even at the lowest detectable levels 
visually within the first 24-48 hours.  
A     B 
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Human and rat IFITM3-eGFP seems to damage the cells in the early hours 
after transfection inducing the protein expressing cells to die within the first 
24-48 hours. 
A possible explanation of the cell induced stress is that the expression of 
the fusion protein induces a dominant negative effect or that IFITM3 fusion 
protein overexpression induces a dosage dependent blocking on the wild 
type IFITM3 protein activity or alters the localization of native IFITM3 
protein. Further experiments are underway to gain further insight into the 
role of IFITM3 over expression. Early research has demonstrated that 
IFITM3 has a role in inhibiting cell proliferation. In agreement, the lab of 
Zucchi has shown that IFITM3 mRNA and protein are up-regulated in 
terminally differentiated cells that are maintained in a quiescent state of cell 
proliferation.  
4.5 ROLE OF IFITM3 IN LA7 CELL PROLIFERATION  
In contrast to the rapid cell loss and detachment of the cells from the 
culture plates with up-regulation of IFITM3-eGFP fusion protein occuring 
with in 72 hours of onset of induced expression (Figures 20 and 25), loss of 
LA7 cells with down-regulation of IFITM3 appeared to be a relavitely slow 
process with cell passaging. To quantify and confirm the qualitivative 
observation that a decrease of SC number occurred with IFITM3 down-
regulation, fluorescence activated cell sorting (FACS) was utilized. LA7 
CSCs transduced with lentivirus containing GFP and shRNA targeting rat 
IFITM3 or GFP alone were used. Transductions efficiency was assessed 
for both conditions and were found to be similar (Fig.27). The decrease of 
LA7 SC number was assessed immediately after IFITM3 down-regulation. 
A reduction of GFP positive population was observed with cells in which 
shRNA against IFITM3 was expressed (Fig.27, A), compared to control. 
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Figure 27. Dot plots obtained from LA7 transduced with a lentivirus for IFITM3 shRNA expression 
(A) and GFP alone (B). Relative percentage of cells for each population are shown, with P4 and P5 
as the GFP positive population. Most of the GFP expressing cells are contained in P4. Increased cell 
passaging is associated with show a decrease in the percentage of GFP positive cells in cells 
transduced with a lentivirus for IFITM3 shRNA expression. The GFP population of cells transduced 
with GFP alone show no decrease in the percentage of GFP positive cells with passaging. 
 
LA7 transduced with the GFP vector show no significant variation of GFP 
positive population in one month of observation (Fig.27, B) where as LA7 
SCs in which IFITM3 was down-regulated disappeared with 3 to 6 passage 
cultures. The decrease of GFP positive population in LA7 transduced with 
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lentivirus containing shRNA targeting IFITM3 suggest that cells in which 
IFITM3 is down-regulated either proliferate less or have reduced SC 
specific self-renewal capacity. While further experiments are necessary to 
validate these results, microarray expression analysis supports that the 
expression of genes regulating cell cycle and/or SC self-renewal is 
specifically altered with down-regulation of IFITM3 in LA7 SCs (Fig.30). 
4.6 MICROARRAY ANALYSIS 
In order to better understand the IFITM3 involvement in mammary 
differentiation and in the stem cell property maintenance, we analyzed the 
transcriptome of IFITM3-depleted LA7 cells compared to LA7 control, using 
micro-array expression analysis. LA7 cells cultured in adherent condition 
were transfected with siRNA or transduced with a lentiviral construct 
containing a short hairpin RNA (shRNA) targeting IFITM3.  
Cell in which IFITM3 down-regulation was approximately of 70% (Fig.28) 
were used for the microarray profile analisys. 
 
Figure 28. Real Time data of LA7 cells transduced with the shRNA for IFITM3 in comparison to 
untreated cells. shRNA for IFITM3 down-regulated the level of mRNA approximately of 70%. 
Vertical bars represent the standard error of the 95% level of confidence. 
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Untreated or untransduced LA7 were used as a control. The data were 
normalized and genes with a fold change of 1.5 were considered for 
analysis. The expression data was compared with two other microarray 
expression data sets: 1) genes differentially expressed when IFITM3 was 
up-regulated following LA7 CSC differentiation induced by DMSO and 2) 
genes differentially expressed in tumors generated in NOD-SCID mice by 
the injection of a single LA7 CSC74. Venn diagrams of overlapping 
biological/molecular pathways suggest the role of IFITM3 in SC/CSC 
differentiation and in tumor development (Fig.29). More than 470 pathways 
are modulated with down-regulation of IFITM3 in LA7 CSCs. The top 
biological pathways represented with the highest adjusted “P” value 
indicate that IFITM3 regulates positively or negatively cell cycle associated 
functions (Table 2), in agreement with observed loss of the SC population 
with IFITM3 down-regulation. 
 
Figure 29. Venn diagrams representing overlapping pathways between LA7 depleted of IFITM3, 
LA7 differentiating and tumor formation of LA7 injected into NOD-SCID mouse. Of all, 26 pathways 
are common to all three conditions. Picture generated by Dr Ettore Mosca, modified. 
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 PATHWAYS  
1 Cell cycle, mitotic 14 DNA replication 
2 
Mitotic cell cycle 
process 
15 Mitotic prometaphase 
3 Mitotic cell cycle 16 Response to alcohol 
4 Cell cycle 17 
Activation of the pre-replicative 
complex 
5 Nuclear division 18 Regulation of cell division 
6 Organelle fission 19 Cell division 
7 Cell cycle 20 Response to radiation 
8 Response to hypoxia 21 
Activation of ATR in response to 
replication stress 
9 
Response to decreased 
oxygen levels 
22 Response to estrogen 
10 
Response to oxygen 
levels 
23 Aging 
11 Mitotic nuclear division 24 MicroRNAs in cancer 
12 
G1 to s cell cycle 
control 
25 Regeneration 
13 
Regulation of cell cycle 
process 
26 Organ regeneration 
 
Table 2. List of the 26 pathways found common in IFITM3 down-regulated cells, tumor formation 
of mice injected LA7 and differentiating LA7. 
More than 120 pathways were found associated with IFITM3 down-
regulation in tumors generated from the injection of single LA7 CSC into the 
fat pads of NOD-SCID mice. The top candidate pathways regulated by 
IFITM3 in tumor development are associated with the regulation of cell 
matrix, motility and adhesion, morphological changes necessary to promote 
tumor development, angiogenesis and cell cycle related functions.  
 
A total of 26 pathways were found to be in common in mammary gland 
normal development and tumor development and be regulated by IFITM3 
(Fig.30). 
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Figure 30. Top 10 responding genes differentially expressed with IFITM3 down-regulation, LA7 
differentiation and LA7 dependent tumor formation. Color intensity indicates the level of gene 
expression in comparison to LA7 CSCs. Picture generated by Dr Ettore Mosca, modified. 
 
A total of 1950 genes was found up-regulated and 1844 genes were down-
regulated. Different analysis was performed on data with the bioinformatics 
tools DAVID, Panther, Kegg. From the resulting clustering of gene by a 
common Gene Ontology and pathways we focused our attention on 3 
groups of transcripts: 1) genes involved in cell cycle, 2) genes associated 
with the SNARE-mediated vesicular transport, 3) olfactory epithelium 
associated genes, typically not expressed in the mammary gland at any 
stage of differentiation (Table 3, 4). 
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Gene ID Gene name LA7 control sh IFITM3 LA7 Differential expression 
NM_001000411 Olr866 5,34165 6,93785 1,59620 
NM_001000413 Olr869 5,45564 6,93889 1,48325 
NM_214828 Olr1378 6,36169 7,60056 1,23887 
NM_001000231 Olr288 5,68993 6,90860 1,21867 
NM_001000526 Olr1457 5,36608 6,57903 1,21295 
NM_001000039 Olr1521 5,16541 6,37065 1,20524 
NM_001000145 Olr104 5,68331 6,85548 1,17217 
NM_001001114 Olr1701 5,70123 6,85524 1,15401 
NM_001000009 Olr1416 5,49742 6,64621 1,14879 
NM_001000748 Olr60 5,50692 6,62516 1,11823 
NM_001000412 Olr867 5,19689 6,28458 1,08769 
NM_001000054 Olr875 5,28214 6,35876 1,07662 
NM_001000788 Olr1388 5,54433 6,61299 1,06866 
NM_001000768 Olr7 5,32855 6,39490 1,06636 
NM_001000264 Olr1768 5,34281 6,40504 1,06224 
NM_001000538 Olr1l 5,64982 6,69759 1,04777 
NM_001000017 Olr1440 6,14413 7,18763 1,04350 
NM_001000425 Olr1111 5,48582 6,52859 1,04277 
NM_001000771 Olr1455 5,86480 6,90605 1,04125 
NM_001000583 Olr857 5,08759 6,12878 1,04120 
Table 3. List of the top 20 genes of the olfactory receptors resulted up-regulated in IFITM3 depleted cells. 
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Cell cycle 
AURKB, BOD1, CAMK2D, CDC20, CDC26, CDCA8, DLGAP5, DNAJC2, 
DSCC1, E2F1, EHMT2, KIFC1, LOC500342, LOC688265, MAD2L2, 
MIS12, MLH1, NEK6, NUDC, PINX1, RGD1309522, RGD1310778, RRS1, 
SGOL2, SKA1, TAF10, TCFE2A, UCHL5IP, WEE1 
Vesicular transport 
LOC366820, LOC366818, STX8, STX12, STX17, STX18, VAMP2, VAMP8, 
VAMP4, YKT6 
Genes specific for the 
olfactory epithelium  
OLR1L , OLR386, OLR104, OLR1061, OLR1076, OLR1090, OLR1095, 
OLR1092, OLR1093, OLR1106, OLR1107, OLR1111, OLR1227, 
OLR1330, OLR1334, OLR1337, OLR1339, OLR1345, OLR1346, 
OLR1350, OLR1352, OLR1353, OLR1355, OLR1525, OLR1365, 
OLR1378, OLR1387, OLR1388, OLR139, OLR1401, OLR1404, OLR1416, 
OLR1423, LOC686792, OLR1424,, OLR1433, OLR1434, OLR1440, 
OLR1448, OLR1454, OLR1455, OLR1457, OLR1458, OLR1462, 
OLR1509, OLR1511, OLR1512, OLR1514, OLR1521, OLR1572, 
OLR1584, OLR1601, OLR1607, OLR1619, OLR1637, OLR1666, 
OLR1667, OLR1701, OLR172, OLR176, OLR1743, OLR1744, OLR1748, 
OLR1746, OLR175, OLR1750, OLR1768, OLR202, OLR218, OLR286, 
OLR287, OLR288, OLR3, OLR303, OLR321, OLR325, OLR326, OLR37, 
OLR39, OLR40, OLR434, OLR44, OLR48, OLR6, OLR60, OLR61, OLR69, 
OLR7, OLR731, OLR733, OLR796, OLR839, OLR856, OLR857, OLR858, 
OLR866, LOC679789, OLR867, OLR862, OLR869, OLR875, OLR927, 
OLR1383, OLR1384, OLR1385, RGD1562157 
Table 4. List of genes and known pathways modulated with IFITM3 down-regulation from 
microarray expression analysis. Cell Cycle and Vesicular Transport genes are down-regulated and 
Olfactory Epithelium genes are up-regulated. 
 
4.7 RT-PCR VALIDATION 
Genes of the Olfactory Receptors (ORs) are expressed in the olfactory 
neurons in the olfactory epithelium of the nose and are not expressed in the 
mammary gland at any stage of development. ORs are a very numerous 
genes family organized in many subfamilies and an olfactory neuron 
express only one single OR. 
Real Time data confirmed that the ORs group is up-regulated in LA7 cells 
where IFITM3 is down-regulated (Fig.31 A).  
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The evidence that the down-regulation of IFITM3 resulted in the expression 
of genes that are not normally expressed in the mammary gland prompted 
us to investigate the molecular mechanism associated with this unexpected 
switch in the expression of the ORs. Since it is known that the expression 
of one single OR in an olfactory neuron is due to activity of epigenetic 
mechanisms that silence the translation of all the other ORs132, we 
hypothesized that the change in expression level of ORs observed in LA7 
in which the down-regulation of IFITM3 was induced, is a consequence of 
epigenetic modifications. We hypothesize that down-regulation of IFITM3 
has a direct effect on the transcription level of gene involved ORs 
repression. 
We analyzed the microarray data to identify genes that regulate epigenetic 
modification and found that genes involved in chromatin remodelling were 
down-regulated (Table 5). 
 
Gene symbol Complete name 
Suv39h1 Suppressor of variegation 3-9 homolog 1 
Setdb1 SET domain, bifurcated 1 
Kdm1b Lysine (K)-specific demethylase 1B 
Prmt3 Protein arginine methyltransferase 3 
Table 5. List of genes involved in chromatin remodelling found down-regulated following IFITM3 
down-regulation. 
 
SUV39H1 and SETDB1 are histone methyltransferase that trimethylate 
lysine 9 of histone 3, that induce gene silencing and transcriptional 
repression, KDM1B is an histone demethylase that regulates histone 3 
lysine 9 methylation, PRMT3 is an arginine methyltransferase that may 
methylate histone 4. 
The expression level of these genes was validated by RT-PCR and the 
results confirm the array data (Fig.31 B). Since as mentioned before, ORs 
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genes are silenced in other tissues, this suggested that IFITM3 down-
regulation may induce epigenetic modification that may re-activate the 
transcription of these tissue specific genes. 
 
 
Figure 31. RT PCR: A) The representative olfactory genes up-regulated in sh-IFITM3 transduced LA7 
cells. B) Representative genes associated with epigenetic machinery down-regulated in sh-IFITM3 
transduced LA7 cells. Vertical bars represent the standard error of the 95% level of confidence. 
Collectively these analyses provide insight into the genes and pathways 
that are regulated by IFITM3 in mammary cell differentiation or tumor 
development. 
0 
2 
4 
6 
8 
10 
12 
CTRL shIFITM3 
OLR1378 
OLR1471 
OLR866 
0 
0,2 
0,4 
0,6 
0,8 
1 
1,2 
CTR shIFITM3 
SUV39H1 
SETDB1 
KDM1B 
PRMT3 
A 
B 
56 
 
5 DISCUSSION 
5.1 ROLE OF IFITM3 IN MAMMARY GLAND DIFFERENTIATION 
The mammary gland is one of the few organ in which differentiation occur 
in the adult life and the unique organ that during the adult life, undergoes 
repeating cycles of regeneration. An intense proliferation program is 
activated at each pregnancy, followed by a multi-steps differentiation 
program that culminates with lactation. Subsequently an apoptosis-
dependent regression process take place with involution 50. These cycles of 
regeneration are maintained by resident stem cells of the mammary gland. 
Mammary gland stem cells therefore, represent a model system for 
identifying epigenomic processes, genes and factors that regulate normal 
cell differentiation and stem cell maintenance. Due in part to the fact that 
the mammary gland undergoes repeated cycles of stem cell dependent 
regeneration, each of these process need to be highly regulated to prevent 
that the gland initiate tumor development. Mammary gland is therefore also 
a model for understanding tumor initiation and progression. 
Development of the mammary gland occurs in stages, beginning in the 
embryo and progressing after birth. A rudimentary system of small ducts is 
present in newborn that at puberty generates into an extensive network of 
ductal trees. At pregnancy, while further ductal growth occurs, most of the 
organ growth is associated with formation of lobules containing alveolar 
buds that secrete milk proteins during lactation. The research of Zucchi’s 
lab. supports that terminal differentiation of alveolar epithelial cells, that is 
completed at parturition requires IFITM3 protein to shuttle from cytoplasm 
to the alveoli cell membrane for the secretion of milk78. Published research 
from the lab demonstrated that IFITM3 is necessary for the formation of 
blister like structures called “domes” that represent terminally differentiated 
mammary gland structures reminiscent of alveoli.  
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Since IFITM3 is already known to be fundamental in one aspect of 
differentiation of mammary gland we choose to investigate if IFITM3 has a 
role in other steps of cellular differentiation. We tested the capacity of the 
cells in which IFITM3 expression was modulated to grow in suspension 
conditions and differentiate into tubuli or cysts and we evaluated if IFITM3 
could affect the stem cell properties and self renewal. Our results 
demonstrate that IFITM3 is necessary for LA7 to differentiate into tubuli and 
for MCF7 to differentiate into cysts when cultured in 3D conditions. 
IFITM3 is a transmembrane protein that localize both at endosomal level 
and plasma membrane. At the cellular membrane it is known to associate 
to lipid rafts and to associate to different protein such as the kinase Fyn or 
the v-ATPase Atp6v0b98. 
IFITM3 hence may interact with some unknown protein involved in 
transduction of signal necessary for differentiation into tubuli, or with protein 
of the collagen matrix and directly act as a transducer of extracellular 
signals, promoting migration of the cells and elongation of the ducts. 
 
5.2 ROLE OF IFITM3 IN CANCER STEM CELLS AND 
MAMMARY GLAND STEM CELLS 
Breast cancer is the second leading cause of death of cancer for women.  
Breast cancer is a very heterogeneous disease which etiology is unknown, 
many causes influence cancer onset, such as hereditary and environmental 
factors, and many genes and pathways are involved in the different types of 
breast tumor. 
Breast cancer research is not only related to molecular mechanisms 
involved in the onset of the pathology but also in the process that lead to 
developing drug resistance and recurrence. 
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Breast cancer is a heterogeneous disease and to explain the origin of the 
many different type of cancer, two theories were formulated: clonal 
evolution and cancer stem cells model. 
LA7 are a CSC model and can grow in non adherent condition to form 
mammosphere, showing self renewal properties typical of a stem cell. We 
decided to investigate the involvement of IFITM3 in the SC properties of 
LA7 as cancer and mammary gland stem cell. 
LA7 cells with down-regulation of IFITM3 show no capacity to survive in 
non adherent conditions and to form spheres. Moreover, down-regulation of 
IFITM3 resulted in loss of propagation capability in LA7, but not in MCF7 or 
myoepithelial cells, which express low levels of native IFITM3, suggesting 
that IFITM3 may play a different role in cells with SC self-renewal 
properties and cells with no SC properties. Our results demonstrate the 
importance of IFITM3 in the LA7 cellular model of mammary SCs and 
CSCs, in which the gene is required for cells differentiation into mammary 
gland structures such as tubuli and for maintenance of the SC properties. 
IFITM3 has been related to cancer and it has been shown to be 
overexpressed in different cancerous tissue, such as colon cancer and 
gastric cancer. In colon cancer IFITM3 seems to be under negative 
regulation of the KLF4 transcription factor133, and IFITM3 overexpression is 
also related to metastasis and proliferation, while reduction of IFITM3 lead 
to decreased proliferation an migration of colon cancer cells. 
Our results are consistent with literature data as IFITM3 seems to be 
related to cancer potential of LA7 cells.  
5.3 ROLE OF IFITM3 IN PROLIFERATION 
Analysis of the transcriptome of IFITM3 depleted LA7 cells unrevealed 
numerous genes of which the expression was altered. We focused on three 
group of gene with common gene ontology and similar known function. 
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IFITM3 has been related to cell cycle and proliferation by different 
authors134–136, and finding cell cycle genes down-regulated with depletion of 
IFITM3 is consistent with literature data. Nonetheless literature does not 
agree upon the role of IFITM3, as some authors suggest an anti-
proliferative effect whereas others link IFITM3 expression to a reduction of 
proliferation. 
FACS data presented in this thesis research suggest that IFITM3 down-
regulation could have an effect on LA7 cell proliferation, since the number 
of cells transduced with the lentiviral IFITM3 shRNA cells decrease with 
passages of culture.  
Comparison of expression data with two other microarray data of cells in 
which IFITM3 is up-regulated by the differentiating agent DMSO and during 
tumor formation generated with LA7 injection into NOD-SCID mouse 
showed 26 pathways common to all three conditions. Most of these 
pathways are related to cell cycle regulation and cellular growth. We are 
currently focusing of the top 10 genes in common to all 26 pathways. 
5.4 ROLE OF IFITM3 IN VESICULAR TRANSPORT 
Another interestingly data emerged from microarray analysis is the down-
regulation of some genes involved in the vesicular transport and fusion of 
small vesicles. Proteins such as vesicle-associated membrane protein 2 
(VAMP2) are known to be involved in the process of formation of a fusion 
pore. 
Since IFITM3 is also involved in blocking viral release from endosome 
through the inhibition of a complete fusion pore formation it is possible that 
it could impedes vesicle fusion of other origin, interacting with protein of the 
Soluble N-ethylmaleimide-sensitive factor (NSF) Attachment protein 
Receptor (SNARE) complex. The SNARE complex is composed of three 
proteins present on the plasma membrane and on the vesicular membrane 
60 
 
that, interacting with each other, promote membrane contact and 
subsequent fusion.  
5.5 ROLE OF IFITM3 IN EPIGENETIC REGULATION 
The most unexpected result we obtained from microarray analysis is the 
finding that the ORs resulted up-regulated. Since ORs are epigenetically 
silenced in order to have only one single OR expressed in an olfactory 
neuron we consequently developed the hypothesis that IFITM3 down-
regulation may induce epigenetic changes of chromatin state. 
The first gene, KDM1B, is an histone demethylase and is involved in 
sensitizing breast cancer cells to a drug inhibiting DNA methyltransferase, 
which then promotes cell cycle arrest and apoptosis137.  
SUV39H1 is a histone trimethylase and it was found responsible for E-
cadherin promoter methylation driven by Snail138,139, which directly interacts 
with SUV39H1. Snail is the main transcriptor factor involved in the epithelial 
to mesenchymal transition (EMT), a process in which epithelial cells 
acquire fibroblast-like properties that allows the cells to migrate.  
EMT is a normal physiological process that takes place during embryo 
development allowing epithelial cells to become mesenchymal, but is also 
involved in tumor when cancer cells acquire motility and spread to blood 
vessel to form metastasis. EMT or an EMT-like process is also involved in 
mammary gland morphogenesis in TEBs elongation, with migration of the 
cap cells which lose polarity and digestion of the extracellular matrix. 
Since LA7 are a cancer stem cell model with capability of metastatization, 
and able to develop into tubuli when properly cultured, we can hypothesize 
a direct effect of SUV39H1 on LA7 properties linked to the presence of 
IFITM3. 
SETDB1 is an histone methyltransferase and has been found involved in 
different type of cancer, such as prostate140 and lung cancer141. In lung 
cancer SETDB1 is found overexpressed and related to activation of the 
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WNT pathway142,143, with increase in proliferation of the cells. WNT is not 
only fundamental for mammary gland development in all the stages of the 
process, but is also involved in cancer development144 and EMT process145–
147. In prostate cancer SETDB1 is also overexpressed and if down-
regulated reduces proliferation and invasiveness of tumor cells. Moreover 
SETDB1 has a role in embryonic stem cell state, as it has been found 
involved in the repression of genes regulating development and 
differentiation148, suggesting a role in preventing a destabilization or in 
maintenance of the ES cell state. 
PRMT3, an arginine methyltransferase that can in vitro methylate a peptide 
of histone 4149, may play a role in cell growth and apoptosis. DAL-1/4.1B is 
a human tumor suppressor which reduces cellular growth and induces 
apoptosis and exert his function through inhibition of PRMT3150,151.  
It may so be possible that PRMT3 must be active and methylate its targets 
in order for a cancerous cell to survive and proliferate. 
Diminished expression of genes responsible for chromatin remodelling 
suggest that IFITM3 is involved in regulating the chromatin state of the cell, 
preventing alterations due to reduced activity of epigenetic enzymes such 
as histone methylase and demethylase, granting maintenance of cellular 
identity and properties, as for instance the self-renewal properties of LA7. 
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6 CONCLUSIONS 
My research supports that IFITM3 is fundamental in the regulation of the 
development of both normal and mammary gland cancer. 
IFITM3 is necessary not only for alveologensis but it is also involved in 
branching morphogenesis, as silencing of the gene abolishes the capability 
of cells to form 3D structures such as the ducts or acini of the mammary 
gland. 
Moreover IFITM3 appears to be necessary for maintenance of mammary 
gland cancer stem cells. 
LA7 CSCs in which IFITM3 is down-regulated lose the capability to survive 
or grow in non adherent conditions, suggesting that IFITM3 may inhibit 
apoptosis or anoikis of CSCs. 
Finally preliminary evidence suggests that IFITM3, acts in mammary gland 
by modulating epigenetic components associated with gene expression and 
the chromatin state of cells.  
Future studies of IFITM3 will confirm its involvement epigenenomic 
regulation in stem cells and in differentiated cells by determining whether 
re-establishment of epigenetic factors can compensate the effects 
observed with IFITM3 down-regulation in luminal differentiated cells and 
MaSCs. 
Moreover we will study the various stages associated with cancer 
progression (including metastasis) with injection into NOD-SCID mice LA7 
cells in which IFTIM3 was down-regulated or up-regulated. Lastly we will 
focus our attention on the other two groups of gene obtained from 
microarray data in order to achieve definitive answers about IFITM3’s role 
in proliferation and in vesicle transport and fusion, functions most recently 
identified in immune response with viral infection. 
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